Controversies Regarding Subclinical Leaflet Thrombosis After TAVR

Published: 25 February 2021

  • Views:

    Views Icon 513
  • Likes:

    Heart Icon 0

Overview

Full programme

  • Views:

    Views Icon 513
  • Likes:

    Heart Icon 0

Overview

A substantial number of patients develop a subclinical leaflet thrombosis (SLT) after transcatheter aortic valve replacement (TAVR).

The thrombus forms on the leaflets, which can lead to valve dysfunction and possibly to early valve degeneration. Multidetector computed tomography is the most sensitive imaging technique at detecting SLT.

Patients on antiplatelet drugs are at higher risk to develop SLT as compared to those on anticoagulants. During the live debate, the experts in the field will discuss controversies concerning SLT, including the routine use of oral anticoagulants and CT exams after TAVR.

Learning Objectives

  • To learn about the natural history, incidence and clinical implications of SLT
  • To learn about the mechanisms that may lead to SLT
  • To understand the diagnostic criteria SLT
  • To discuss the prevention and treatment options for SLT

Audience

  • Interventional cardiologists with focus on TAVR procedures
  • Cardiac Imaging specialists (Echocardiography, Computer Tomography)
  • General cardiologists
  • Specialists interested in management of antithrombotic therapies after TAVR

Series overview

Part 1

Subclinical leaflet thrombosis after TAVR: Numbers and facts

1 session

  • Subclinical leaflet thrombosis after TAVR: Numbers and facts

    Watch now

Part 2

Debate: Patients should receive routine CT screening after TAVR to exclude subclinical valve thrombosis

3 sessions

Part 3

Debate: Patients should be routinely discharged on oral anticoagulants for prevention of subclinical valve thrombosis after TAVR

3 sessions

Faculty biographies